DelveInsight launched a new report on “Glaucoma Market Insights, Epidemiology, and Market Forecast-2032“.
The Glaucoma market report provides current treatment practices, emerging drugs, Glaucoma market share of the individual therapies, and current and forecasted Glaucoma market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Glaucoma treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Glaucoma market.
Glaucoma: An Overview
According to the American Academy of Ophthalmology, glaucoma describes a group of conditions in which there is characteristic cupping of the optic disc with corresponding visual field defects due to retinal ganglion cell loss. It is a progressive condition and the most common cause of irreversible blindness worldwide. The two major categories of glaucoma are open-angle glaucoma and narrow-angle glaucoma/angle-closure glaucoma. The “angle” in both cases refers to the drainage angle inside the eye that controls the outflow of the watery fluid (aqueous) which is being produced inside the eye.
Visit to know more about the Glaucoma, treatment algorithms in different geographies, and patient journey contact to receive a sample @ https://www.delveinsight.com/report-store/glaucoma-market
Glaucoma Market
The Glaucoma market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Glaucoma market trends by analyzing the impact of current Glaucoma therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
Glaucoma Market Key Findings:
- The market size of Glaucoma in the 7MM was estimated to be USD 4,466 million in 2021.
- Of this, in the 7MM, the majority of the market share is accommodated by Prostaglandin analogs generating USD 2,086 million, followed by Fixed combinations generating USD 768 million while others contributed the least towards the market share, with USD 73 million, in 2021.
According to DelveInsight, the Glaucoma market in 7MM is expected to witness a major change in the study period 2019-2032.
Request a sample and discover more about the report offerings at: https://www.delveinsight.com/sample-request/glaucoma-market
Glaucoma Epidemiology
The Glaucoma epidemiology section provides insights into the historical and current Glaucoma patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Glaucoma market report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Glaucoma Epidemiology Insights:
- The total diagnosed prevalent population of Glaucoma in the 7MM was 11,048,000 in 2021, which is expected to increase in the forecast period (2022-2032).
- Among the five European countries, Germany had the highest diagnosed prevalent population of Glaucoma with 1,115,113 cases, followed by Italy and France in 2021. On the other hand, Spain had the lowest.
Explore more about the Glaucoma Epidemiology at: https://www.delveinsight.com/report-store/glaucoma-market
Glaucoma Drugs Uptake
This section focuses on the rate of uptake of the potential Glaucoma drugs recently launched in the Glaucoma market or expected to get launched in the market during the study period 2019-2032. The analysis covers Glaucoma market uptake by drugs; patient uptake by therapies; and sales of each drug.
Glaucoma Drugs Uptake helps in understanding the drugs with the most rapid uptake, and the reasons behind the maximal use of new drugs, and allows the comparison of the drugs on the basis of Glaucoma market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Glaucoma Pipeline Development Activities
The Glaucoma report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Glaucoma’s key players involved in developing targeted therapeutics.
Glaucoma Therapeutics Assessment
Major key companies such as Allergan, Sun Pharma Advanced Research Company Limited, Santen Pharmaceutical Co., Ltd., D.Western Therapeutics Institute (DWTI), Kowa Ltd., Alcon, Senju Pharmaceuticals and Otsuka Pharmaceuticals Co. Ltd., TearClear, are working proactively in the Glaucoma therapeutics market to develop novel therapies which will drive the Glaucoma treatment market in the upcoming years.
Learn more about the emerging therapies & key companies at: https://www.delveinsight.com/report-store/glaucoma-market
Glaucoma Report Key Insights
1. Glaucoma Patient Population
2. Glaucoma Market Size and Trends
3. Key Cross Competition in the Glaucoma Market
4. Glaucoma Market Dynamics (Key Drivers and Barriers)
5. Glaucoma Market Opportunities
6. Glaucoma Therapeutic Approaches
7. Glaucoma Pipeline Analysis
8. Glaucoma Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Glaucoma Market
Table of Contents
1. Key Insights
2. Executive Summary
3. Glaucoma Competitive Intelligence Analysis
4. Glaucoma Market Overview at a Glance
5. Glaucoma Disease Background and Overview
6. Glaucoma Patient Journey
7. Glaucoma Epidemiology and Patient Population
8. Glaucoma Treatment Algorithm, Current Treatment, and Medical Practices
9. Glaucoma Unmet Needs
10. Key Endpoints of Glaucoma Treatment
11. Glaucoma Marketed Products
12. Glaucoma Emerging Therapies
13. Glaucoma Seven Major Market Analysis
14. Attribute Analysis
15. Glaucoma Market Outlook (7 major markets)
16. Glaucoma Access and Reimbursement Overview
17. KOL Views on the Glaucoma Market
18. Glaucoma Market Drivers
19. Glaucoma Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/